Brief: Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2
09/09/2026 12:50
BRIEF-Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2 Sept 9 (Reuters) - Serina Therapeutics, Inc. SER.A:
SERINA THERAPEUTICS INC: REPORTS COHORT 1 OBSERVATIONS FROM SER-252 REGISTRATIONAL STUDY IN ADVANCED PARKINSON’S DISEASE AND ADVANCES TO COHORT 2
SERINA THERAPEUTICS - EXPECTS TO REPORT TOPLINE DATA FROM THE SINGLE-ASCENDING-DOSE PORTION OF THE STUDY IN FIRST HALF OF 2027
SERINA THERAPEUTICS - BLINDED COHORT 1 OBSERVATIONS SHOWED PHARMACOKINETIC PROFILE CONSISTENT WITH SUSTAINED APOMORPHINE EXPOSURE SER-252
Source text: [ID:n0001708599-26-000054]
Further company coverage: SER.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Serina Therapeutics
See all newsBrief: Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2
Brief: Serina Therapeutics - Offers Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments - SEC Filing
Serina Therapeutics Q2 net loss widens on higher expenses
Brief: Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors
Brief: Serina Therapeutics Completes Sentinel Dosing In Cohort 1 Of Phase 1B Registrational Trial Of SER-252